Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine-A for Cognitive Dysfunction in Schizophrenia
NCT01012830Phase 4Unknown
- Sponsor
- VA Nebraska-Western Iowa Health Care System
- Start
- Dec 2009
- Primary completion
- Dec 2010
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Huperzine A in schizophrenia, sponsored by VA Nebraska-Western Iowa Health Care System. Primary endpoint: MATRICS Consensus Cognitive Battery at 8 weeks. Status: unknown.
02
Drugs
Huperzine A
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01012830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012830.